drugset / Trial / NCT01271374

Changes in Endothelial Function and Biomarkers in African Americans (AA) With Metabolic Syndrome

NCT01271374

Phase 4 Unknown 80 enrolled InVasc Therapeutics, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to compare the effects of Azor (a combination of amlodipine and olmesartan) with Hyzaar ( a combination of losartan and hydrochlorothiazide) on the thin lining on the inside of blood vessels. These cells help keep blood vessels healthy and blood pressure normal.

Timeline

Start
2010-04
Primary completion
2011-06
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amlodipine Other / unclassified 5 mg
Comparator Amlodipine Other / unclassified 10 mg
Comparator Hydrochlorothiazide Unknown 12.5 mg
Comparator Hydrochlorothiazide Unknown 25 mg
Comparator Losartan Other / unclassified 50 mg
Comparator Losartan Other / unclassified 100 mg
Comparator Olmesartan Other / unclassified 20 mg
Comparator Olmesartan Other / unclassified 40 mg
Comparator Spironolactone Small molecule 25 mg

Indications